ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs MXN
20.6314
0.00%
Brent Oil
76.495
0.00%
Bitcoin
98,325.64
0.12%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE

  6. Yarrl (0LZC) Cotización

Yarrl

Yarrl (0LZC)

LSE
2.84
0.00
(0.00%)
Cerrado 05 Enero 10:30AM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
2.84
Postura de Compra
0.00
Postura de Venta
0.00
Volume Operado de la Acción
0.00
0.00 Rango del Día 0.00
2.84 Rango de 52 semanas 2.84
Capitalización de Mercado [m]
19.755M
Precio Anterior
2.84
Precio de Apertura
-
Hora
(O)
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
0.00
Acciones en circulación
6,956,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
14.00
Beneficio por acción (BPA)
0.2
turnover
30.71M
Beneficio neto
1.41M

Acerca de Yarrl

Sector
Communications Equip, Nec
Industria
Communications Equip, Nec
Sitio web
www.yarrl.pl
Sede
Krakow, Pol
Fundado
-
Yarrl is listed in the Communications Equip sector of the London Stock Exchange with ticker 0LZC. The last closing price for Yarrl was PLN2.84. Over the last year, Yarrl shares have traded in a share price range of PLN 2.84 to PLN 2.84.

Yarrl currently has 6,956,000 shares in issue. The market capitalisation of Yarrl is PLN19.76 million. Yarrl has a price to earnings ratio (PE ratio) of 14.00.

0LZC Últimas noticias

Más noticias
No news to show yet.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1002.842.842.8400DE
4002.842.842.8400DE
12002.842.842.8400DE
26002.842.842.8400DE
52002.842.842.8400DE
156002.842.842.8400DE
260002.842.842.8400DE

0LZC - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Yarrl?
El precio actual de las acciones de Yarrl es PLN 2.84
¿Cuántas acciones de Yarrl están en circulación?
Yarrl tiene 6,956,000 acciones en circulación
¿Cuál es la capitalización de mercado de Yarrl?
La capitalización de mercado de Yarrl es PLN 19.76M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Yarrl?
Yarrl ha negociado en un rango de PLN 2.84 a PLN 2.84 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Yarrl?
El ratio precio/beneficio de Yarrl es 14
¿Cuál es el ratio de efectivo a ventas de Yarrl?
El ratio de efectivo a ventas de Yarrl es 0.64
¿Cuál es la moneda de reporte de Yarrl?
Yarrl presenta sus resultados financieros en PLN
¿Cuál es el último ingresos anual de Yarrl?
El último ingresos anual de Yarrl es PLN 30.71M
¿Cuál es el último beneficio anual de Yarrl?
El último beneficio anual de Yarrl es PLN 1.41M
¿Cuál es la dirección registrada de Yarrl?
La dirección registrada de Yarrl es UL. STANIS��AWA SKAR��Y��SKIEGO 14, KRAKOW, 31-866
¿Cuál es la dirección del sitio web de Yarrl?
La dirección del sitio web de Yarrl es www.yarrl.pl
¿En qué sector industrial opera Yarrl?
Yarrl opera en el sector COMMUNICATIONS EQUIP, NEC

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discusión

Ver feed completo
mining101 mining101 10 segundos hace
Superb
MEGL
benz280c benz280c 7 minutos hace
Speak louder and maybe you will convince somebody that this is how you really feel. No need to be insecure around your fellow investors.
GDVM
rx7171 rx7171 14 minutos hace
In addition MABs are approved for only a limited portion of the AD population, whereas Blarcamasine appears to be effective in 70-80% of the ITT population with its strongest efficacy in the 70% with wild type Sigma-1.
AVXL
TheHound TheHound 15 minutos hace
Learn how to use the bull market support band with that chart and you’ll have a powerful tool under your belt!
XRPUSD
Investor2014 Investor2014 18 minutos hace
When I say that the totality of information is what Anavex rely on it does take into account the pretty ineffective SOC, associated risks and inconveniences for patients.

Still any drug regulatory process must and should look carefully at the data to ensure that neither type one or tw
AVXL
nowwhat2 nowwhat2 23 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
BTCUSD
rx7171 rx7171 24 minutos hace
Yes that spike to $23 in June of 2021 was driven entirely by the excellent Phase II data for PDD.

Yet now after completing the AD 2b/3 trial and having an EMA MAA accepted for evaluation the share price is barely half that number!

I understand the company being very ca
PDD
sunspotter sunspotter 29 minutos hace
Black Cat Moan was one of my favorites back in the day:

https://youtu.be/cxN-frB1UbI?si=Ph6XMC3omR0rRlmR

Edit: auto correct changed Moan to Moana. The cultural prevalence of Disney.
Investor2014 Investor2014 31 minutos hace
The ex-biotech executive is back in the Rett trap posting mode - hope it goes better with the biased approach this time.

Listing all the site PI’s is not world class peer review WGT confirmation.
AVXL
nowwhat2 nowwhat2 32 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
sunspotter sunspotter 34 minutos hace
I rather think you missed the point. It’s not that higher doses of GALT’s drug are toxic, it’s that they are ineffective.

Given the purported mechanism, that almost certainly means lower doses are too, and that the implication that the lower dose worked is merely an artefact.
GALT
nowwhat2 nowwhat2 37 minutos hace
Just learnt of the Total 3 today.......Appears to be a good thing to have learnt of.

3 month
https://investorshub.advfn.com/uimage/uploads/2025/1/5/siwcoTOTAL_3_!_4_3M_JUNCT_DAY_1.jpg



Because how the overall mkt resolves itself is gonna'r have con
XRPUSD
CrossFireTrader CrossFireTrader 40 minutos hace
I try to avoid Krispy Kreme's af all costs. Thanks for your insight...
GDVM
skitahoe skitahoe 40 minutos hace
Dstock, you may be very right about the data from compassionate use being included, but if it is, I would think that the protocols used on every one of those patients would need to be included as none are specifically on the trial protocol. It's essentially anecdotal evidence, but it could all add
NWBO
Pickme2 Pickme2 41 minutos hace
Stop wasting our time with your ongoing Manipulated nonsense.... Just read the S-1 
Filed with the sec.... 


ATMH
georgejjl georgejjl 43 minutos hace
The MABs are no where near being the standard of care for treating Alzheimer’s patients.
AVXL
benz280c benz280c 44 minutos hace
Phone died when responding to that. In summary, I think the 24/7 is multi-pronged. It is necessary for the kind of business that Veemost is and will be, which aligns it and will help it qualify for Gold. I do not recall it expressly said that Gold was reached and turned down. Not saying that didn't
GDVM
Sheepdog Sheepdog 58 minutos hace
Really? So you think the SEC is going to start arresting OTC Scammers and Pump/Dumpers? I hope so...about time.
GCAN
Hummingbird2 Hummingbird2 60 minutos hace
$GTII ~ Just listen in the first 5 mins about $GTII 🛫 after March? https://www.youtube.com/watch?v=Ag2f2rDlq5g
GTII
Jane1999 Jane1999 60 minutos hace
Here the CEO : https://www.wsj.com/market-data/quotes/CA/XCNQ/TWOH/company-people/executive-profile/149699
TWOH
Curious Bystander Curious Bystander 1 hora hace
The Expert Market was set up by the SEC for several very specific reasons. But you could generally say that a security lands in that market when a company is either UNABLE or UNWILLING to file certain SEC-required forms.

UNABLE or UNWILLING. Hmmmm…..I wonder which category Quantum
FLCX
CometNebula81 CometNebula81 1 hora hace
What is everyone's opinion on if or when dividends may be restored and if so what much would we be looking at in dividends? Let's you have 100,000 shares what would you be getting every year?
FNMA
Steady_T Steady_T 1 hora hace
Wouldn't the MABS have to be better than donepezil and memantine to get approved making them the new SOC?

That doesn't mean the MABS are selling well.
AVXL

Su Consulta Reciente

LSE
0LZC
Yarrl
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados